Jeppe Gustafsson/ Shuttershock

18 June 2024Big PharmaMarisa Woutersen

Teva secures stay on Orange Book inhaler patent delisting

New Jersey court grants 30-day stay days after ordering the removal of five patents for asthma inhalers from FDA Orange Book | Decision follows ruling favouring Amneal Pharmaceuticals, which argued the patents were improperly listed.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York